MicroRNAs as biomarkers for endometriosis

12077,803

17/517014

November 02, 2021

Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.

YALE UNIVERSITY (New Haven, CT, US)

Yale University (New Haven, CT, US)

1. A method of treating endometriosis in a subject, the method comprising: (I) determining that the subject has endometriosis by: (a) providing a blood, serum, or plasma sample comprising nucleic acids from the subject; (b) obtaining a detected level of at least one miRNA, wherein the level of the at least one miRNA is determined by performing an amplification reaction on at least one miRNA selected from the group consisting of: miR-125b, miR143, miR-145, miR-150, miR-342, miR-451, miR-3613, miR-500, miR-18, miR-214, miR-126, miR-553, miR-4668, and miR-6755; (c) detecting endometriosis in the subject based on the level of the at least one miRNA; and (II) administering a treatment for the endometriosis to the subject, thereby treating the endometriosis.

2. The method of claim 1 , wherein the blood, serum, or plasma sample is a serum sample.

3. The method of claim 1 , wherein the at least one miRNA is a circulating, cell-free miRNA.

4. The method of claim 1 , wherein the treatment is selected from the group consisting of: a non-steroidal anti-inflammatory drug, a hormone therapy, a hormonal contraceptive, surgical laparoscopy, chemotherapy, and immunotherapy.

5. The method of claim 1 , wherein the treatment is surgical laparotomy.

6. The method of claim 1 , wherein the treatment is selected from the group consisting of: a gonadotropin-releasing hormone agonist, a progestin, an oral contraceptive, an aromatase inhibitor, and a statin.

7. The method of claim 1 , wherein the at least one miRNA comprises at least two miRNAs selected from the group consisting of: miR-125b, miR-150, miR-342, miR-451a, miR-3613, and let-7b.

8. The method of claim 1 , wherein the at least one miRNA comprises at least four miRNAs selected from the group consisting of: miR-125b, miR-150, miR-342, miR-451a, miR-3613, and let-7b.

9. The method of claim 1 , wherein the at least one miRNA comprises miR-342.

10. The method of claim 1 , wherein the at least one miRNA comprises miR-451a.

11. The method of claim 1 , wherein the at least one miRNA comprises miR-125b.

12. The method of claim 1 , wherein the at least one miRNA comprises miR-150.

13. The method of claim 1 , wherein the at least one miRNA comprises miR-3613.

14. The method of claim 1 , wherein the endometriosis is detected with a sensitivity of at least 80%.

15. The method of claim 1 , wherein the at least one miRNA is selected from the group consisting of: miR-125b, miR-150, miR-342, and miR-451a, and is at least 20% up-regulated in the blood, plasma, or serum sample compared with a control.

16. The method of claim 1 , wherein the level of miR-3613 is at least 20% down-regulated in the blood, plasma or serum sample compared with a control.

10982282 April 2021 Taylor
11220713 January 2022 Taylor
11315660 April 2022 Taylor
20090317820 December 2009 Wong
20120093936 April 2012 Lindenberg
20140024590 January 2014 Weidhaas
20140342937 November 2014 Jeanson-Leh
20150267257 September 2015 Nagarkatti
20160251718 September 2016 Giudice
20170175190 June 2017 Taylor
20180127828 May 2018 Belli
20190276893 September 2019 Taylor
20200206303 July 2020 Bowerman
20200321077 October 2020 Taylor
20210180134 June 2021 Taylor
20220049312 February 2022 Taylor
103237901 August 2013
2924126 September 2015
2924126 April 2018
2014513521 June 2014
2015504655 February 2015
2010056337 May 2010
2012103355 August 2012
2012112883 August 2012
2013148151 October 2013
2015073972 May 2015
2015128671 September 2015
2015148919 October 2015
2018044979 March 2018
2019046494 March 2019
2020092672 May 2020
2020223238 November 2020

Turchinovich et al., 2011, “Characterization of extracellular circulating microRNA.” Nucleic Acids Res, 39:7223-7233. cited by applicant
U.S. Appl. No. 15/129,663 Examiner Interview Summary dated Nov. 20, 2020, 5 pages. cited by applicant
Ulivi et al., 2014, “miRNAs as non-invasive biomarkers for lung cancer diagnosis.” Molecules, 19:8220-8237. cited by applicant
Vodolazkaia et al., “Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis.” Hum Reprod, 27: 2698-2711, Jun. 26, 2012. cited by applicant
Voelkerding et al. (Clinical Chemistry, 2009 vol. 55:641-658). cited by applicant
Wang et al., “Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor.” Gynecol Oncol, 119: 586-593, Jul. 2010. cited by applicant
Wang et al., “Serum miR-146a and miR-223 as potential new biomarkers for sepsis.” Biochem Biophys Res Commun, 394: 184-188, Feb. 2010. cited by applicant
Wang et al., 2012, “Circulating MIR-125b as a marker predicting chemoresistance in breast cancer.” PLoS One, 7: e34210 (8 pages). cited by applicant
Wang et al., 2012, “Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects.” Clin Chem Lab Med, 50:1423-1428. cited by applicant
Wang et al., 2013, “Circulating microRNAs identified in a genome-wide serum microRNA expression analysis as noninvasive biomarkers for endometriosis.” J Clin Endocrinol Metab, 98:281-289. cited by applicant
Wang et al., 2015, “MicroRNA-125b may function as an oncogene in lung cancer cells.” Mol Med Rep, 11(5):3880-3887. cited by applicant
Wang, et al. Analysis of Serum microRNA Profile by Solexa Sequencing in Women With Endometriosis. Reprod Sci. Oct. 2016;23(10):1359-70. doi: 10.1177/1933719116641761. Epub Jul. 13, 2016. cited by applicant
Weber, et al. The microRNA spectrum in 12 body fluids. Clinical chemistry 56.11 (2010): 1733-1741. cited by applicant
Wen-Tao Wang et al, “Circulating MicroRNAs Identified in a Genome-Wide Serum MicroRNA Expression Analysis as Noninvasive Biomarkers for Endometriosis”, Journal of Clinical Endocrinology & Metabolism, (Jan. 1, 2013), vol. 98, No. 1, doi:10.1210/jc.2012-2415, ISSN 0021-972X, pp. 281-289, XP055127854. cited by applicant
Xu et al., 2014, “Tumor-suppressing effects of miR451 in human osteosarcoma.” Cell Biochem Biophys, 69(1):163-168. cited by applicant
Yang et al., “MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.” Cancer Res, 68: 425-433, Jan. 15, 2008. cited by applicant
Yang et al., “MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.” Cancer Res, 68: 10307-10314. cited by applicant
Zhao et al., 2006, “KRAS variation and risk of endometriosis.” Molecular Human Reproduction. vol. 12, No. 11, pp. 671-676. cited by applicant
Zhao et al., 2012, “Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy.” Clin Chem, 58:896-905. cited by applicant
Zhu et al., 2008, “Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury.” Hepatology, 48: 1430-1439. cited by applicant
Zhu et al., 2014, Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet, 5:149, 7 pages. cited by applicant
Afshar, et al. Changes in eutopic endometrial gene expression during the progression of experimental endometriosis in the baboon, Papio anubis. Biology of reproduction 88.2 (2013): 44-1. cited by applicant
Aitana Braza-Bols et al, “MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors”, Human Reproduction, GB, (Mar. 6, 2014), vol. 29, No. 5, doi:10.1093/humrep/deu019, ISSN 0268-1161, pp. 978-988, XP055402965. cited by applicant
Akao et al., 2007, “MicroRNA-143 and- 145 in colon cancer.” DNA Cell Biol, 26: 311-320. cited by applicant
Arroyo et al., 2011, “Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.” Proc Natl Acad Sci U S A, 108:5003-5008. cited by applicant
Azmy et al. (Medical Research Journal: Dec. 2012—vol. 11:pp. 1-13). cited by applicant
Bandiera et al., 2015, “miR-122—a key factor and therapeutic target in liver disease . . . ” J Hepatol, 62:448-457. cited by applicant
Bell et al., 2013, “Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?” Cell Mol Life Sci, 70: 2657-2675. cited by applicant
Brest et al., “A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease.” Nat Genet, 43: 242-245, Jan. 10, 2011. cited by applicant
Chang et al. BMPR1B Up-Regulation via a miRNA Binding Site Variation Defines Endometriosis Susceptibility and CA125 Levels. PLoS One 2013, 8:e80630-e80630, 10 pages. cited by applicant
Chen et al. MIR-125b regulates endometrial receptivity by targeting MMP26 in women undergoing IVF-ET with elevated progesterone on HCG priming day. Scientific reports 6 (2016): 25302. (12 pages). cited by applicant
Chen et al., 2008, “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.” Cell Res, 18:997-1006. cited by applicant
Chen et al., 2014, “MicroRNA 125b suppresses the proliferation and osteogenic differentiation of human bone marrow derived mesenchymal stem cells.” Mol Med Rep, 9(5):1820-1826. cited by applicant
Cheng, et al. Print CG, Charnock-Jones DS. Activation of mutated K-ras in donor endometrial epithelium and stroma promotes lesion growth in an intact immunocompetent murine model of endometriosis. J Pathol 224.2 (2011): 261-269. cited by applicant
Cho et al. Aromatase inhibitor regulates let-7 expression and let-7f-induced cell migration in endometrial cells from women with endometriosis. Fertility and sterility 106.3 (2016): 673-680. cited by applicant
Cho et al., 2012, “Urinary vitamin D-binding protein is elevated in patients with endometriosis.” Hum Reprod, 27:515-522. cited by applicant
Cho et al., 2015, “Circulating microRNAs as potential biomarkers for endometriosis.” Fertil Steril, 103(5):1252-1260. cited by applicant
Co-pending U.S. Appl. No. 17/289,882, inventor Taylor; Hugh, filed Apr. 29, 2021. cited by applicant
Co-pending U.S. Appl. No. 17/703,321, inventors Taylor; Hugh et al., filed Mar. 24, 2022. cited by applicant
Co-pending U.S. Appl. No. 17/834,762, inventors Bowerman; Heather et al., filed Jun. 7, 2022. cited by applicant
Co-pending U.S. Appl. No. 16/860,792, filed Apr. 28, 2020 (82 pages). cited by applicant
Cosar, et al. Serum microRNAs as diagnostic markers of endometriosis: a comprehensive array-based analysis. Fertil Steril. Aug. 2016;106(2):402-9. doi: 10.1016/j.fertnstert.2016.04.013. Epub May 11, 2016. cited by applicant
Coskun et al., 2012, “MicroRNAs in inflammatory bowel disease—pathogenesis, diagnostics and therapeutics . . . ” World J Gastroenterol, 18:4629-4634. cited by applicant
D'Hooghe, et al. Lack of an Association between a Polymorphism in the KRAS 3′ Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study.Gynecologic and obstetric investigation 84.6 (2019):575-582. cited by applicant
D'Alessandra et al., 2010, “Circulating microRNAs are new and sensitive biomarkers of myocardial infarction.” Eur Heart J, 31: 2765-2773. cited by applicant
Dai et al., 2012, MiR-199a attenuates endometrial stromal cell invasiveness through suppression of the IKKβ/NF-κB pathway and reduced interleukin-8 expression. Mol Hum Reprod, 18: 136-145. cited by applicant
Dorval et al., 2013, “Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers . . . ” Front Mol Neurosci, 6:24 (6 pages). cited by applicant
EP15769372.2 Extended Search Report dated Sep. 8, 2017. (11 pages). cited by applicant
EP17847431.8 Extended European Search Report dated Jul. 22, 2020 (15 pages). cited by applicant
EP17847431.8 The Partial Supplemental European Search Report dated Apr. 8, 2020. (14 pages). cited by applicant
EP18852025.8 Extended Search Report dated Aug. 3, 2021. cited by applicant
EP20194688.6 Extended European Search Report dated Feb. 22, 2021. cited by applicant
Gallo et al., 2012, “The majority of microRNAs detectable in serum and saliva is concentrated in exosomes.” PLoS One, 7: e30679 (5 pages). cited by applicant
Ghazal et al. H19 IncRNA alters stromal cell growth via IGF signaling in the endometrium of women with endometriosis. EMBO molecular medicine 7.8 (2015): 996-1003. cited by applicant
Giray et al., 2014, “Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.” Mol Biol Rep, 41(7):4513-4519. cited by applicant
Graham et al. The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival. Human Reproduction 30.3 (2015): 642-652. cited by applicant
Grechukhina et al., 2012, “A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.” EMBO Mol Med, 4: 206-217. cited by applicant
Hou et al., “The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes.” Biochim Biophys Acta, 1819: 1113-1122, Jun. 2012. cited by applicant
Iorio et al., “MicroRNA gene expression deregulation in human breast cancer.” Cancer Res, 65: 7065-7070, Aug. 15, 2005. cited by applicant
Jarry et al., 2014, The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol, 8: 819-829. cited by applicant
Jia et al., 2013, “Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis.” Hum Reprod, 28:322-330. cited by applicant
Jin et al., 2013, “Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases . . . ” Cell Mol Neurobiol, 5:601-613. cited by applicant
Joshi et al. Altered expression of microRNA-451 in eutopic endometrium of baboons (Papio anubis) with endometriosis. Human Reproduction 30.12 (2015): 2881-2891. cited by applicant
Kennedy et al. (Hum Reprod., 2005 vol. 20:2698-2704). cited by applicant
Lai et al., 2014, “Modulated expression of human peripheral blood microRNAs from infancy to adulthood and its role in aging.” Aging Cell, 13:679-689. cited by applicant
Laudanski et al., Expression of selected tumor suppressor and oncogenes in endometrium of women wiht endometriosis, Hum Reprod. Aug. 2009;24(8): 1880-90. cited by applicant
Lawrie et al., “Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma . . . ” Br J Haematol, 141: 672-675, Jan. 2, 2008. cited by applicant
Liu et al., 2014, “MicroRNAs as potential biomarkers for gastric cancer.” World J Gastroenterol, 20:12007-12017. cited by applicant
Liu et al., 2016, “MicroRNA 451 inhibits neuroblastoma proliferation, invasion and migration by targeting macrophage migration inhibitory factor.” Mol Med Rep, 13(3): 2253-60; doi: 10.3892/mmr. 4770. cited by applicant
Luong, et al. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis. Human reproduction 27.12 (2012): 3616-3621. cited by applicant
Marsh et al., “Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium . . . ” Fertil Steril, 89: 1771-1776, Dec. 15, 2008. cited by applicant
Matamala et al., 2015, “Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.” Clin Chem, 61(8):1098-1106. cited by applicant
May et al., 2010, “Peripheral biomarkers of endometriosis: a systematic review.” Hum Reprod, 16:651-674. cited by applicant
Medical News Today downloaded from Sputum: Definition, colors, causes, and when to see a doctor (medicalnewstoday.com on Dec. 1, 2021. cited by applicant
Mitchell et al., “Circulating microRNAs as stable blood-based markers for cancer detection.” Proc Natl Acad Sci USA, 105: 10513-10518, May 12, 2008. cited by applicant
Mol, et al. “The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis.” Fertil Steril, 70: 1101-1108, Dec. 1998. cited by applicant
Mongroo et al., “IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.” Cancer Res, 71: 2172-2182, Jan. 20, 2011. cited by applicant
Moustafa, et al. Accurate diagnosis of endometriosis using serum microRNAs. Am J Obstet Gynecol. Mar. 9, 2020. pii: S0002-9378(20)30321-5. doi: 10.1016/j.ajog.2020.02.050. [Epub ahead of print], 28 pages. cited by applicant
Mu, et al. Expression, regulation and function of MicroRNAs in endometriosis.Die Pharmazie—An International Journal of Pharmaceutical Sciences 71.8 (2016): 434-438. cited by applicant
Murri et al., 2013, “Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression.” J Clin Endocrinol Metab, 98:E1835-1844. cited by applicant
Nagel et al., “Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer.” Cancer Res, 68: 5795-5802, Jul. 15, 2008. cited by applicant
Nakasa et al., “Expression of microRNA-146 in rheumatoid arthritis synovial tissue.” Arthritis Rheum, 58: 1284-1292, May 2008. cited by applicant
Naqvi et al., 2016, “Endometriosis Located Proximal to or Remote From the Uterus Differentially Affects Uterine Gene Expression.” Reprod Sci, 23:186-191. cited by applicant
Nematian et al. Systemic inflammation induced by microRNAs: endometriosis-derived alterations in circulating microRNA 125b-5p and Let-7b-5p regulate macrophage cytokine production. The Journal of Clinical Endocrinology & Metabolism 103.1 (2017): 64-74. cited by applicant
Nisenblat, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. May 1, 2016;(5):CD012179. (654 pages). cited by applicant
Notice of Allowability dated Dec. 14, 2021 for U.S. Appl. No. 17/184,894 (pp. 1-2). cited by applicant
Notice of Allowability dated Feb. 1, 2021 for U.S. Appl. No. 16/329,436 (pp. 1-3). cited by applicant
Notice of Allowability dated Sep. 9, 2021 for U.S. Appl. No. 15/129,663 (pp. 1-5). cited by applicant
Notice of Allowance dated Jan. 27, 2021 for U.S. Appl. No. 16/329,436 (pp. 1-8). cited by applicant
Notice of Allowance dated Jul. 26, 2021 for U.S. Appl. No. 15/129,663 (pp. 1-5). cited by applicant
Notice of Allowance dated Sep. 21, 2021 for U.S. Appl. No. 17/184,894 (pp. 1-7). cited by applicant
Office Action (Final Rejection) dated Jun. 29, 2022 for U.S. Appl. No. 15/129,663 (pp. 1-15). cited by applicant
Office Action (Non-Final Rejection) dated May 23, 2023 for U.S. Appl. No. 15/129,663 (pp. 1-15). cited by applicant
Office Action dated Apr. 8, 2020 for U.S. Appl. No. 16/329,436 (pp. 1-19). cited by applicant
Office Action dated Aug. 4, 2021 for U.S. Appl. No. 17/184,894 (pp. 1-6). cited by applicant
Office Action dated Dec. 6, 2021 for U.S. Appl. No. 15/129,663 (pp. 1-17). cited by applicant
Office Action dated Jan. 15, 2020 for U.S. Appl. No. 15/129,663 (pp. 1-12). cited by applicant
Office Action dated Jul. 29, 2019 for U.S. Appl. No. 15/129,663 (pp. 1-11). cited by applicant
Office Action dated Nov. 1, 2018 for U.S. Appl. No. 15/129,663 (pp. 1-12). cited by applicant
Office Action dated Oct. 23, 2020 for U.S. Appl. No. 15/129,663 (pp. 1-17). cited by applicant
Office Action dated Oct. 27, 2020 for U.S. Appl. No. 16/329,436 (pp. 1-20). cited by applicant
Pan et al., “The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression.” Mol Hum Reprod, 13: 797-806 (Retracted), Aug. 31, 2007. cited by applicant
PCT/US2015/022986 International Preliminary Report on Patentability dated Sep. 27, 2016. (10 pages). cited by applicant
PCT/US2015/022986 International search report with written opinion dated Aug. 10, 2015, 11 pages. cited by applicant
PCT/US2017/049284 International Search Report and Written Opinion dated Nov. 28, 2017. (15 pages). cited by applicant
PCT/US2018/048649 International Search Report dated Jan. 2, 2019. (14 pages). cited by applicant
Rafaella Petracco et al, “MicroRNA 135 Regulates HOXA10 Expression in Endometriosis”, Journal of Clinical Endocrinology & Metabolism, (Dec. 1, 2011), vol. 96, No. 12, doi:10.1210/jc.2011-1231, ISSN 0021-972X, pp. E1925-E1933, XP055187310. cited by applicant
Ramon et al., “microRNAs expression in endometriosis and their relation to angiogenic factors.” Hum Reprod, 26: 1082-1090, Jan. 17, 2011. cited by applicant
Reis et al., 2012, “Diagnostic value of serum activin A and follistatin levels in women with peritoneal, ovarian and deep infiltrating endometriosis.” Hum Reprod, 27:1445-1450. cited by applicant
Rekker et al., 2013, “Circulating microRNA Profile throughout the menstrual cycle.” PLoS One, 8: e81166, (6 pages). cited by applicant
Resnick et al., 2008, “The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.” Gynecol Oncol, 112: 55-59. cited by applicant
Ruan Yu et al., “[Study on microRNA expression in endometrium of luteal phase and its relationship with infertility of endometriosis]”, Chung-Hua Fu Ch'an K'O Tsa Chih—Chinese Journal of Obstetricsand Gyneco, Chinese Medical Journals Publ. House, CN, (Dec. 1, 2013), vol. 48, No. 12, ISSN 0529-567X, pp. 907-910, XP008170439. cited by applicant
Sayed et al., 2014, “Diagnosis, Prognosis and Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases.” Heart Lung Cir, 23:503-510. cited by applicant
Schwarzenbach et al., 2014, “Clinical relevance of circulating cell-free microRNAs in cancer.” Nat Rev Clin Oncol, 11:145-156. cited by applicant
Small et al., “Pervasive roles of microRNAs in cardiovascular biology.” Nature, 469: 336-342, Jan. 20, 2011. cited by applicant
Sredni et al., 2011, “A Parallel Study of mRNA and microRNA Profiling of Peripheral Blood in Young Adult Women.” Front Genet, 2:49 (6 pages). cited by applicant
Suryawanshi et al., 2013, “Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.” Clin Cancer Res, 19:1213-1224. cited by applicant
Tang et al., “MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.” Cell Signal, 26: 1420-1426, Mar. 2014. cited by applicant
Taylor, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist . . . N Engl J Med. Jul. 6, 2017;377(1):28-40. cited by applicant
Teague et al., “MicroRNA-regulated pathways associated with endometriosis.” Mol Endocrinol, 23: 265-275, Dec. 2008, 11 pages. cited by applicant
Teague et al., 2010, The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update, 16: 142-165. cited by applicant
Office Action (Notice of Allowance and Fees Due (PTOL-85)) dated Jan. 18, 2024 for U.S. Appl. No. 15/129,663 (pp. 1-13). cited by applicant
Yang et al., 2008, “MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.” Cancer Res, 68: 10307-10314. cited by applicant

edspgr.12077803